Core Insights - Telomir Pharmaceuticals, Inc. has announced new in vitro results indicating that Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, suggesting a potential advancement in epigenetic therapy [1] Company Summary - Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing therapies that target the root causes of cancer, aging, and age-related diseases [1] - The company is listed on NASDAQ under the ticker TELO [1] Industry Summary - The results from Telomir-1 may represent a novel frontier in epigenetic therapy, an area where no existing candidates have demonstrated comparable breadth [1] - The inhibition of three members of the KDM5 histone demethylase family by Telomir-1 highlights the potential for innovative therapeutic approaches in the field of epigenetics [1]
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies